A postulated role of testosterone for prevention of cisplatin gonadal toxicity

Medical Hypotheses

Volumn 68, Issue 3, 2007, Pages 525-527

  Aminsharifi, A R ^a   Talaei, T ^a   Kumar, V ^a   Sabayan, B ^a   Samani, S ^a   Mohamadhoseini, E ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUTAMIDE; GONADORELIN AGONIST; TESTOSTERONE;

ARTICLE; AZOOSPERMIA; BLOOD TESTIS BARRIER LEAKAGE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; DISEASE SEVERITY; GERM CELL TUMOR; GONAD TOXICITY; HORMONE ACTION; HUMAN; LEYDIG CELL DYSFUNCTION; MALE INFERTILITY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REPRODUCTIVE TOXICITY; SPERMATOGENESIS; TESTIS ATROPHY; TESTIS CANCER;

ANTITOXINS; CISPLATIN; HUMANS; MALE; TESTICULAR NEOPLASMS; TESTIS; TESTOSTERONE;

EID: 33845931180     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.08.023     Document Type: Article

References (22)

1. Bergstrom R., Adami H.O., Mohner M., Zatonski W., Storm H., Ekbom A., et al. Increase in testicular cancer incidence in six European countries: a birth cohort phenomenon. J Natl Cancer Inst 88 (1996) 727-733
2. Bosl G.J., and Motzer R.J. Testicular germ-cell cancer. N Engl J Med 337 (1997) 242-253
3. Bosl G.J., Vogelzang N.J., Goldman A., Fraley E.E., Lange P.H., Levitt S.H., et al. Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet 2 (1981) 970-973
4. Weissbach L. Guidelines for the diagnosis and therapy of testicular cancer and new developments. Urol Int 63 (1999) 46-56
5. Foster R.S., and Nichols C.R. Testicular cancer: What's new in staging, prognosis, and therapy?. Oncology 13 (1999) 1689-1694 discussion 1697-700, 1703
6. Schmoll H.J. Treatment of testicular tumours based on risk factors. Curr Opin Urol 9 (1999) 431-438
7. Ishikawa T., Kamidono S., and Fujisawa M. Fertility after high-dose chemotherapy for testicular cancer. Urology 63 (2004) 137-140
8. Pectasides D., Pectasides M., Farmakis D., Nikolaou M., Koumpou M., Kostopoulou V., et al. Testicular function in patients with testicular cancer treated with bleomycin-etoposide-carboplatin (BEC (90)) combination chemotherapy. Eur Urol 45 (2004) 187-193
9. Boekelheide K. Mechanisms of toxic damage to spermatogenesis. J Natl Cancer Inst Monogr 34 (2005) 6-8
10. Petersen P.M., Giwercman A., Skakkebaek N.E., and Rorth M. Gonadal function in men with testicular cancer. Semin Oncol 25 (1998) 224-233
11. Drasga R.E., Einhorn L.H., Williams S.D., Patel D.N., and Stevens E.E. Fertility after chemotherapy for testicular cancer. J Clin Oncol 1 (1983) 179-183
12. Nakazumi H., Sasano H., Maehara I., Ozaki M., Tezuka F., and Orikasa S. Estrogen metabolism and impaired spermatogenesis in germ cell tumors of the testis. J Clin Endocrinol Metab 81 (1996) 1289-1295
13. Morrish D.W., Venner P.M., Siy O., Barron G., Bhardwaj D., and Outhet D. Mechanisms of endocrine dysfunction in patients with testicular cancer. J Natl Cancer Inst 82 (1990) 412-418
14. Fossa S.D., Theodorsen L., Norman N., and Aabyholm T. Recovery of impaired pretreatment spermatogenesis in testicular cancer. Fertil Steril 54 (1990) 493-496
15. Meistrich M.L., Finch M., da Cunha M.F., Hacker U., and Au W.W. Damaging effects of fourteen chemotherapeutic drugs on mouse testis cells. Cancer Res 42 (1982) 122-131
16. Meistrich M.L. Stage-specific sensitivity of spermatogonia to different chemotherapeutic drugs. Biomed Pharmacother 38 (1984) 137-142
17. Pogach L.M., Lee Y., Gould S., Giglio W., Meyenhofer M., and Huang H.F. Characterization of cis-platinum-induced Sertoli cell dysfunction in rodents. Toxicol Appl Pharmacol 98 (1989) 350-361
18. Maines M.D., Sluss P.M., and Iscan M. cis-platinum-mediated decrease in serum testosterone is associated with depression of luteinizing hormone receptors and cytochrome P-450scc in rat testis. Endocrinology 126 (1990) 2398-2406
19. Howell S.J., and Shalet S.M. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr 34 (2005) 12-17
20. Waxman J. Chemotherapy and the adult gonad: a review. J R Soc Med 76 (1983) 144-148
21. Kangasniemi M., Wilson G., Huhtaniemi I., and Meistrich M.L. Protection against procarbazine-induced testicular damage by GnRH-agonist and antiandrogen treatment in the rat. Endocrinology 136 (1995) 3677-3680
22. Recchia F., Saggio G., Amiconi G., Di Blasio A., Cesta A., Candeloro G., et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106 (2006) 514-523